Page last updated: 2024-11-04

muconolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

muconolactone: RN given refers to unlabeled parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-oxo-2,5-dihydro-2-furylacetate : A monocarboxylic acid anion that is the conjugate base of 5-oxo-2,5-dihydro-2-furylacetic acid, formed via deprotonation of the carboxy group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23615314
CHEBI ID58372
MeSH IDM0119085

Synonyms (11)

Synonym
4-carboxylatomethyl-4-hydroxyisocrotonolactone
(5-oxo-2,5-dihydrofuran-2-yl)acetate
CHEBI:58372
5-oxo-2,5-dihydro-2-furylacetate anion
5-oxo-2,5-dihydro-2-furylacetate(1-)
5-oxo-2,5-dihydro-2-furylacetate
(+)-4-hydroxy-4-carboxymethylisocrotonolactone
muconolactone
DTXSID60985243
Q27125735
2-(5-oxo-2h-furan-2-yl)acetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monocarboxylic acid anionA carboxylic acid anion formed when the carboxy group of a monocarboxylic acid is deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
superpathway of aromatic compound degradation3349

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]